Market revenue in 2023 | USD 16.8 million |
Market revenue in 2030 | USD 27.8 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.12% in 2023. Horizon Databook has segmented the Thailand cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Thailand has been focusing on improving its healthcare infrastructure and promoting high-quality drug production, attracting international pharmaceutical companies to partner with local manufacturers for cell and gene therapy CDMOs.
Major players in the cell & gene therapy bioanalytical testing services market are expanding their manufacturing capabilities and capacities to meet the increasing demand for pharmaceuticals in Thailand.
Furthermore, key pharmaceutical companies are collaborating with local players to expand their market presence & strengthen their contract manufacturing capabilities in the country. For instance, in August 2023, Genepeutic Bio collaborated with Cytiva to establish Thailand’s first GMP-certified cell therapy facility, enhancing its CDMO capabilities and supporting the production of CAR T-cell therapies for blood cancer in the region.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Thailand cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account